Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Vivani Medical, Inc. is a clinical-stage company with a cash balance of $14.6 million as of September 30, 2026, down from $16.2 million at year-end 2025. The company remains pre-revenue, focusing on the development of product candidates like NPM-139 and NPM-133, and reported a total liability of $22.1 million primarily driven by lease obligations.
Artelo Biosciences reported a net loss of $7.15 million for the nine months ended September 30, 2026, compared to $8.71 million in the prior year period. The company strengthened its balance sheet through equity financing, ending the quarter with $4.44 million in cash and cash equivalents, up from $0.6 million at the start of the year.
Imunon, Inc. reported a net loss of $10.8 million for the nine months ended September 30, 2026, compared to $10.3 million in the prior year period. The company's cash position decreased to $4.0 million from $8.8 million at year-end 2025, while total liabilities increased significantly due to the issuance of new notes payable.
Chenghe Acquisition III Co. reported a net income of $2,633,792 for the nine months ended September 30, 2026, primarily driven by $3,235,400 in interest earned on cash held in the Trust Account. As a shell company, it has not yet generated operating revenue and is currently focused on identifying a target for its initial Business Combination.
Accelerant Holdings reported third quarter 2026 financial results, highlighted by a 27% year-over-year growth in Exchange Written Premium to $1.33 billion. Despite a GAAP net loss of $9.2 million, the company achieved adjusted net income of $38.2 million and reaffirmed its pending merger with Thoma Bravo, expected to close in the first half of 2027.
“The third quarter continued to show the strength of the Accelerant Risk Exchange, with Exchange Written Premium growing 27% year-over-year to $1.33 billion. We added 26 MGAs during the quarter, maintaining the upward momentum of our high-quality, specialty underwriting talent.”
Jeff Radke, Accelerant’s Chairman and Chief Executive Officer
“We delivered another quarter of disciplined growth, with operating revenue of $280.2 million and adjusted EBITDA of $71.3 million. Our fee-based businesses, which we define as consolidated results less the Underwriting segment, delivered $84.5 million of adjusted EBITDA, representing growth of 75% year over year.”
Linda S. Huber, Accelerant’s Chief Financial Officer
Imunon, Inc. reported financial results for the third quarter ended September 30, 2026, and provided updates on its lead clinical candidate IMNN-001 for advanced ovarian cancer. The company highlighted its Phase 3 OVATION 3 study and a recent Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to support further development of IMNN-001.
“IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer. The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer
“We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position. Through our agreement to transition ThermoDox® to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer
SeaStar Medical reported Q3 2026 financial results, highlighted by a 247% increase in net revenue to $635,000 driven by adoption of its QUELIMMUNE therapy. The company also announced that its NEUTRALIZE-AKI pivotal clinical trial for adult patients is nearly 75% enrolled and it has submitted the first module of its PMA application to the FDA.
Term
Q3 2026
“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications. And we continue to build momentum in educating the critical care pediatric health care community.”
Eric Schlorff, CEO of SeaStar Medical
“The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval.”
CorMedix reported Q3 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, while maintaining its full-year 2026 revenue guidance. The company also highlighted its pending acquisition of Heron Therapeutics assets and a new $150 million term loan facility to support the transaction and operations.
Term
Q3 2026
“CorMedix will be entering 2027 with two meaningful potential growth drivers. First, our pending acquisition of the Heron assets adds four commercial products used in institutional settings of care and is expected to be immediately accretive to earnings and free cash flow upon closing.”
Joseph Todisco, Chairman & Chief Executive Officer
Charlotte's Web Holdings reported a net loss of $20.7 million for the nine months ended September 30, 2026, compared to $18.3 million in the prior year. Revenue decreased to $31.4 million from $36.6 million, while the company significantly improved its balance sheet by converting $50.8 million in convertible debentures into common shares.
LASE Corp. reported a net loss of $8.57 million for the nine months ended September 30, 2026, compared to a loss of $8.11 million in the prior year period. Total assets increased significantly to $15.81 million from $9.45 million at year-end 2025, primarily driven by a substantial increase in current assets following multiple public offerings and warrant inducement exercises.
Latch, Inc. (DOOR) reported Q3 2026 results featuring 18% software revenue growth and significant gross margin expansion to 55.2%. While total revenue declined 18.9% to $14.1 million due to lower hardware volume, the company improved its Adjusted EBITDA loss and launched its OpenDOOR developer platform.
Term
Q3 2026
“The third quarter results reflect our continued focus on driving profitability, highlighted by our improvement in gross margin. Our priorities are clear: strengthen our best-in-class integrated hardware and software platform, streamline operations, and build a more profitable and sustainable company.”
David Lillis, Chief Executive Officer
“We are leaning into what we do best and exiting non-core operations to focus our resources on higher-margin offerings. The restructuring plan we announced in August, which is expected to reduce annualized operating costs by $10 million to $12 million, is progressing as planned and should accelerate our path to profitability.”
Sagimet Biosciences reported third quarter 2026 financial results and provided a corporate update on its Phase 3 AURORA clinical trial for denifanstat in moderate to severe acne. The company highlighted a pro forma cash position of $356 million following a $115 million equity financing in October, which is expected to fund operations through mid-2029.
“Building on the positive Phase 3 results from our license partner Ascletis, we have initiated our pivotal U.S. AURORA Phase 3 clinical trial. With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA.”
ERock reported its first profitable quarter as a public company for Q3 2026, with revenue growing nearly 4x quarter-over-quarter to $152.8 million. The company achieved positive net income of $8.9 million and reaffirmed its full-year 2026 revenue guidance of $435 million to $465 million.
Term
Q3 2026
“We executed well in the third quarter, with record production and deliveries that drove record quarterly revenue and profitability. We began construction at the El Paso Electric facility for Meta, and that project remains on track for completion in mid-2027. We are expanding our manufacturing capacity by 900 MW per year with a new facility in Houston (Atlas). When complete, our total capacity is expected to reach 2.1 GW per year to serve the strong demand for our product. Since the end of the quarter, we added new bookings of more than $300 million, setting a new backlog record and providing revenue and margin visibility into 2028. Our differentiated product and service offerings continue to resonate with customers, and we remain focused on disciplined expansion to meet their needs.”
John Carrington, Chief Executive Officer of ERock
“The third quarter marked an inflection point with revenue growing nearly 4x quarter-over-quarter, driving our first profitable quarter as a public company. We reported $8.9 million of net income and $12.6 million of Adjusted EBITDA. This reflected an improvement of $76.6 million of net income and $26.6 million of Adjusted EBITDA, demonstrating the operating leverage embedded in our business. We expect continued revenue and profitability growth in the fourth quarter and are reaffirming our 2026 guidance. Our robust balance sheet and strong liquidity, coupled with our backlog and unique products and services, give us confidence to expand our manufacturing capacity to meet strong customer demand.”
Go Go Buyers, Inc. reported zero revenue for the nine months ended September 30, 2026, compared to $43,724 in the prior year period. The company incurred a net loss of $56,080 for the first nine months of 2026 and expressed substantial doubt about its ability to continue as a going concern due to a lack of stabilized revenue.
DPC Holdings PLC reported a significant revenue increase to $308.1 million for the quarter ended September 27, 2026, and achieved a net income of $31.8 million compared to a net loss in the prior year period. The company successfully completed an initial public offering during the nine-month period, resulting in a substantial improvement in its equity position and a reduction in total liabilities from $1,859.0 million to $529.5 million.
For the quarter ended September 30, 2026, Latch, Inc. reported total revenue of $14.1 million, a decrease from $17.4 million in the prior year period. The company recognized a significant $13.6 million goodwill impairment charge, contributing to a net loss of $20.5 million compared to a $6.6 million loss in the same quarter of 2025.
Enovix reported Q3 2026 financial results with revenue of $11.0 million, a 38% increase year-over-year, driven by strong demand in the drone and defense sectors. The company achieved a record non-GAAP gross margin of 34.5% and issued new 2027 revenue guidance of $65 million to $85 million.
“The 100,000-battery order and the first MX1-B01 production order reflect our ability to convert our pipeline into orders. The MX1-B01 has now been sampled by more than 30 industry-leading aerial drone accounts with very positive feedback.”
Steve Bakos, newly appointed Chief Revenue Officer and General Manager of Enovix
Solo Brands, Inc. reported a significant increase in cash and cash equivalents to $40.2 million as of September 30, 2026, compared to $20.0 million at year-end 2025. However, total assets decreased from $360.3 million to $322.8 million, driven by lower inventory levels and accounts receivable, while the company continues to manage a substantial long-term debt load of $249.8 million.
Taysha Gene Therapies reported third quarter 2026 financial results and provided a corporate update on its TSHA-102 gene therapy program for Rett syndrome. The company completed its BLA-enabling manufacturing campaign and expects to report topline 6-month interim data and receive FDA feedback on its BLA submission pathway in the first half of 2027.
“During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a potential BLA submission for TSHA-102. With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed across all studies, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome.”
Sean P. Nolan, Chairman and Chief Executive Officer of Taysha
Falcon’s Beyond Global reported Q3 2026 consolidated revenue of $7.3 million, an 80% increase year-over-year, driven by attraction and creative services. The company narrowed its consolidated net loss to $7.7 million and reported a contracted pipeline of $28.0 million for its Attractions and Creative divisions.
Term
Q3 2026
“Our third-quarter results demonstrate continued progress in our growth strategy as we move from building pipeline to executing and delivering major projects. The VAI project announced earlier this year is now underway, bringing together the integrated capabilities of Falcon's Creative and Falcon's Attractions to work across creative design, engineering and attraction delivery.”
Cecil D. Magpuri, Chief Executive Officer of Falcon’s Beyond
Capstone Holding Corp. reported Q3 2026 revenue of $20.0 million, a 46% year-over-year increase, and achieved operating income of $0.4 million. The company updated its full-year 2026 revenue guidance to $70 million, citing higher interest rates slowing housing activity, while noting that its organic sales growth continues to outperform the broader market.
Term
Q3 2026
“We grew revenue 46% and generated income from operations in a difficult housing market. Each of our operating businesses has outperformed its respective market this year, with growth accelerating in the third quarter.”
Solo Brands reported third quarter 2026 net sales of $43.7 million, a 17.6% decrease year-over-year, alongside a net loss of $20.8 million. Despite the revenue decline, the company improved its Adjusted EBITDA margin and generated $6 million in operating cash flow through disciplined cost management and reduced promotional activity.
Term
Q3 2026
“While the third quarter is typically our seasonally smallest sales quarter, we continued to make measurable progress strengthening the business. We improved segment profitability, generated more than $6 million of operating cash flow, and further advanced our transformation strategy through disciplined execution, cost management, and operational efficiency initiatives.”
John Larson, President and Chief Executive Officer
“While revenue performance remains below our expectations, we are encouraged by improving consumer engagement and the strong response to recent product innovation. Products launched over the past year for our Solo Stove segment represented nearly half of our website sales during the quarter, highlighting the strength of our innovation pipeline and the value of our brand portfolio.”
John Larson, President and Chief Executive Officer
Altimmune reported third quarter 2026 financial results and provided a business update on its pemvidutide clinical programs. The company ended the quarter with $480 million in cash and is progressing its Phase 3 PERFORMA trial in MASH and preparing for an End-of-Phase 2 meeting with the FDA for its AUD program in December 2026.
“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide. Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community.”
Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
“In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide’s potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.”
Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
Intuitive Machines reported record third-quarter 2026 financial results, achieving revenue of $269 million and positive free cash flow of $33 million. The company ended the quarter with a record backlog of $1.9 billion, driven by significant contract wins including NASA's $10 billion CLPS 2 IDIQ award and the acquisition of Goonhilly Earth Station.
Term
Q3 2026
“In the third quarter, we delivered record financial performance across the board. These results are an important proof point in our transformation from a company that advanced the state of lunar exploration into a next-generation space prime developing and integrating the technology, infrastructure and services that enable customers to achieve their differentiated missions across space.”
Steve Altemus, CEO
“As we look to turn the corner into 2027, we remain laser focused on IM-3 along with our first Altus-1 lunar satellite, which remains on track for a planned launch in the March/April timeframe. In addition, our emphasis will be to continue to scale execution and accelerate growth. We expect to convert contracted backlog into revenue through repeatable production, operational excellence, and reliable customer delivery.”
Grace Therapeutics reported a net loss of $17.9 million for the six months ended September 30, 2026, primarily driven by a $13.5 million impairment of intangible assets related to GTx-102 and GTx-101. The company strengthened its liquidity through a $9.2 million private placement in August 2026, providing sufficient cash to fund operations for at least 12 months.
Lumexa Imaging Holdings reported a net income of $7.2 million for the third quarter of 2026, a significant recovery from a $3.5 million loss in the prior year period. Total revenues grew to $272.0 million, driven by increases in net patient service and management fee revenue, while the company maintained a strong cash position of $90.0 million.
For the nine months ended September 30, 2026, BTCS Inc. reported total revenues of $8.7 million and a net loss of $49.5 million, primarily driven by $30.6 million in realized losses on digital asset transactions and $11.2 million in impairment losses. This represents a significant downturn from the $52.2 million net income reported in the prior year period, despite a substantial increase in DeFi-related revenue.
Taysha Gene Therapies reported a net loss of $128.2 million for the nine months ended September 30, 2026, compared to $81.1 million in the prior year, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through an underwritten public offering that raised approximately $215.7 million, ending the period with $422.8 million in cash and cash equivalents.
Falcon's Beyond Global, Inc. reported that as of November 12, 2026, it had 49,226,743 Class A and 72,169,750 Class B shares outstanding. The company disclosed substantial doubt about its ability to continue as a going concern due to current liquidity resources and noted material adverse impacts from impairments of intangible assets and equity method investments.
Capstone Holding Corp. reported net sales of $54.1 million for the nine months ended September 30, 2026, a significant increase from $34.4 million in the prior year. Despite higher sales, the company incurred a net loss of $3.9 million for the period, though this was an improvement over the $4.4 million net loss reported in 2025.